{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T11:38:05Z","timestamp":1778672285925,"version":"3.51.4"},"reference-count":38,"publisher":"Elsevier BV","issue":"2-3","license":[{"start":{"date-parts":[[2008,4,1]],"date-time":"2008-04-01T00:00:00Z","timestamp":1207008000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2008,4]]},"DOI":"10.1016\/j.ejphar.2008.01.036","type":"journal-article","created":{"date-parts":[[2008,2,6]],"date-time":"2008-02-06T13:44:33Z","timestamp":1202305473000},"page":"213-221","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Inhibiting wild-type and C299S mutant AKR1B10; a homologue of aldose reductase upregulated in cancers"],"prefix":"10.1016","volume":"584","author":[{"given":"Malkhey","family":"Verma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans-Joerg","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wahajul","family":"Haq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy R.","family":"O'Connor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edmund","family":"Maser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ganesaratnam K.","family":"Balendiran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2008.01.036_bb0005","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/j.bcp.2005.06.029","article-title":"Fibrates inhibit aldose reductase activity in the forward and reverse reactions","volume":"70","author":"Balendiran","year":"2005","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejphar.2008.01.036_bb0010","first-page":"311","article-title":"Chemistory of fibrates","volume":"1","author":"Balendiran","year":"2007","journal-title":"Curr. Chem. Biol."},{"key":"10.1016\/j.ejphar.2008.01.036_bb0015","doi-asserted-by":"crossref","first-page":"9547","DOI":"10.1016\/S0021-9258(18)60566-6","article-title":"The aldo\u2013keto reductase superfamily. cDNAs and deduced amino acid sequences of human aldehyde and aldose reductases","volume":"264","author":"Bohren","year":"1989","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2008.01.036_bb0020","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/978-1-4615-2904-0_29","article-title":"Cys298 is responsible for reversible thiol-induced variation in aldose reductase activity","volume":"328","author":"Bohren","year":"1993","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.ejphar.2008.01.036_bb0025","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/0003-2697(76)90527-3","article-title":"A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein\u2013dye binding","volume":"72","author":"Bradford","year":"1976","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.ejphar.2008.01.036_bb0030","doi-asserted-by":"crossref","first-page":"11429","DOI":"10.1074\/jbc.273.19.11429","article-title":"Identification and characterization of a novel human aldose reductase-like gene","volume":"273","author":"Cao","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2008.01.036_bb0035","doi-asserted-by":"crossref","first-page":"33539","DOI":"10.1074\/jbc.271.52.33539","article-title":"Specifically targeted modification of human aldose reductase by physiological disulfides","volume":"271","author":"Cappiello","year":"1996","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2008.01.036_bb0040","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1042\/bj20021818","article-title":"Human aldose reductase and human small intestine aldose reductase are efficient retinal reductases: consequences for retinoid metabolism","volume":"373","author":"Crosas","year":"2003","journal-title":"Biochem. J."},{"key":"10.1016\/j.ejphar.2008.01.036_bb0045","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.2337\/diabetes.51.12.3486","article-title":"Mechanisms of the triglyceride- and cholesterol-lowering effect of fenofibrate in hyperlipidemic type 2 diabetic patients","volume":"51","author":"Forcheron","year":"2002","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2008.01.036_bb0050","first-page":"912","article-title":"Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease. Fibrate Consensus Group","volume":"81","author":"Fruchart","year":"1998","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ejphar.2008.01.036_bb0055","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1158\/1078-0432.CCR-04-1238","article-title":"Overexpression of the aldo\u2013keto reductase family protein AKR1B10 is highly correlated with smokers' non-small cell lung carcinomas","volume":"11","author":"Fukumoto","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejphar.2008.01.036_bb0060","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/BF00302723","article-title":"Fenofibrate and human liver. Lack of proliferation of peroxisomes","volume":"53","author":"Gariot","year":"1983","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.ejphar.2008.01.036_bb0065","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0303-7207(02)00098-9","article-title":"The peroxisome proliferator-activated receptor alpha (PPARalpha): role in hepatocarcinogenesis","volume":"193","author":"Gonzalez","year":"2002","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.ejphar.2008.01.036_bb0070","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0008-6215(00)90401-4","article-title":"Direct measurement of the rate of ring opening of d-glucose by enzyme-catalyzed reduction","volume":"148","author":"Grimshaw","year":"1986","journal-title":"Carbohydr. Res."},{"key":"10.1016\/j.ejphar.2008.01.036_bb0075","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1001\/archopht.1990.01070110050024","article-title":"A randomized trial of sorbinil, an aldose reductase inhibitor, in diabetic retinopathy. Sorbinil Retinopathy Trial Research Group","volume":"108","author":"Group","year":"1990","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.ejphar.2008.01.036_bb0080","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1038\/208856a0","article-title":"Nature of the hepatomegalic effect produced by ethyl-chlorphenoxyisobutyrate in the rat","volume":"208","author":"Hess","year":"1965","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2008.01.036_bb0085","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S0167-4781(98)00109-2","article-title":"Sequence and expression levels in human tissues of a new member of the aldo\u2013keto reductase family","volume":"1399","author":"Hyndman","year":"1998","journal-title":"Biochim. Biophys. Acta."},{"key":"10.1016\/j.ejphar.2008.01.036_bb0090","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/0003-9861(82)90219-3","article-title":"Affinity purification and glucose specificity of aldose reductase from bovine lens","volume":"216","author":"Inagaki","year":"1982","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.ejphar.2008.01.036_bb0095","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/S0006-2952(97)84253-0","article-title":"A new nomenclature for the aldo\u2013keto reductase superfamily","volume":"54","author":"Jez","year":"1997","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejphar.2008.01.036_bb0100","doi-asserted-by":"crossref","first-page":"855","DOI":"10.2337\/diacare.13.8.855","article-title":"Lowering of plasma glucose concentrations with bezafibrate in patients with moderately controlled NIDDM","volume":"13","author":"Jones","year":"1990","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejphar.2008.01.036_bb0105","doi-asserted-by":"crossref","first-page":"7431","DOI":"10.1158\/0008-5472.CAN-07-0003","article-title":"Clinical validity of the lung cancer biomarkers identified by bioinformatics analysis of public expression data","volume":"67","author":"Kim","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejphar.2008.01.036_bb0110","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1080\/14756360600720887","article-title":"WY 14,643 inhibits human aldose reductase activity","volume":"21","author":"Klemin","year":"2006","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.ejphar.2008.01.036_bb0115","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1124\/dmd.105.007971","article-title":"Purification and characterization of AKR1B10 from human liver: role in carbonyl reduction of xenobiotics","volume":"34","author":"Martin","year":"2006","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejphar.2008.01.036_bb0120","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2165\/00003088-199834020-00003","article-title":"Clinical pharmacokinetics of fibric acid derivatives (fibrates)","volume":"34","author":"Miller","year":"1998","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejphar.2008.01.036_bb0125","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/0167-4838(91)99006-E","article-title":"Purification and characterization of the recombinant human aldose reductase expressed in baculovirus system","volume":"1078","author":"Nishimura","year":"1991","journal-title":"Biochim. Biophys. Acta."},{"key":"10.1016\/j.ejphar.2008.01.036_bb0130","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1007\/s00109-005-0678-9","article-title":"Peroxisome proliferator-activated receptor-alpha and liver cancer: where do we stand?","volume":"83","author":"Peters","year":"2005","journal-title":"J. Mol. Med."},{"key":"10.1016\/j.ejphar.2008.01.036_bb0135","doi-asserted-by":"crossref","first-page":"24833","DOI":"10.1016\/S0021-9258(18)35839-3","article-title":"Involvement of cysteine residues in catalysis and inhibition of human aldose reductase. Site-directed mutagenesis of Cys-80, -298, and -303","volume":"267","author":"Petrash","year":"1992","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2008.01.036_bb0140","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1107\/S0108270104032573","article-title":"Fenofibric acid","volume":"61","author":"Rath","year":"2005","journal-title":"Acta Crystallogr C."},{"key":"10.1016\/j.ejphar.2008.01.036_bb0145","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/283397a0","article-title":"Hypolipidaemic hepatic peroxisome proliferators form a novel class of chemical carcinogens","volume":"283","author":"Reddy","year":"1980","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2008.01.036_bb0150","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1056\/NEJM199908053410604","article-title":"Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-density Lipoprotein Cholesterol Intervention Trial Study Group","volume":"341","author":"Rubins","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2008.01.036_bb0155","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/0006-2952(90)90490-C","article-title":"Inhibition of aldehyde reductase by aldose reductase inhibitors","volume":"40","author":"Sato","year":"1990","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejphar.2008.01.036_bb0160","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/hep.510270408","article-title":"New member of aldose reductase family proteins overexpressed in human hepatocellular carcinoma","volume":"27","author":"Scuric","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/j.ejphar.2008.01.036_bb0165","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jmb.2006.08.011","article-title":"Expect the unexpected or caveat for drug designers: multiple structure determinations using aldose reductase crystals treated under varying soaking and co-crystallisation conditions","volume":"363","author":"Steuber","year":"2006","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.ejphar.2008.01.036_bb0170","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S0969-2126(97)00216-5","article-title":"A \u2018specificity\u2019 pocket inferred from the crystal structures of the complexes of aldose reductase with the pharmaceutically important inhibitors tolrestat and sorbinil","volume":"5","author":"Urzhumtsev","year":"1997","journal-title":"Structure"},{"key":"10.1016\/j.ejphar.2008.01.036_bb0175","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/978-1-4615-5871-2_55","article-title":"Physiological substrates of human aldose and aldehyde reductases","volume":"414","author":"Vander Jagt","year":"1996","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.ejphar.2008.01.036_bb0180","doi-asserted-by":"crossref","first-page":"9847","DOI":"10.1073\/pnas.90.21.9847","article-title":"Refined 1.8\u00a0\u00c5 structure of human aldose reductase complexed with the potent inhibitor zopolrestat","volume":"90","author":"Wilson","year":"1993","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejphar.2008.01.036_bb0185","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1002\/ijc.22933","article-title":"Aldo\u2013keto reductase family 1 B10 gene silencing results in growth inhibition of colorectal cancer cells: implication for cancer intervention","volume":"121","author":"Yan","year":"2007","journal-title":"Int. J. Cancer."},{"key":"10.1016\/j.ejphar.2008.01.036_bb0190","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1111\/j.1525-1438.2007.00932.x","article-title":"Aldo\u2013keto reductase family 1, member B10 in uterine carcinomas: a potential risk factor of recurrence after surgical therapy in cervical cancer","volume":"17","author":"Yoshitake","year":"2007","journal-title":"Int. J. Gynecol. Cancer."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299908001106?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299908001106?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T08:18:25Z","timestamp":1684225105000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299908001106"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,4]]},"references-count":38,"journal-issue":{"issue":"2-3","published-print":{"date-parts":[[2008,4]]}},"alternative-id":["S0014299908001106"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2008.01.036","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2008,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibiting wild-type and C299S mutant AKR1B10; a homologue of aldose reductase upregulated in cancers","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2008.01.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}